Survival Among Patients with Adenocarcinoma of the Pancreas: A Population-based Study (United States)

Cress, Rosemary D.; Yin, Daixin; Clarke, Lisa; Bold, Richard J.; Holly, Elizabeth A.

doi:10.1007/s10552-005-0539-4

Cited by 177 publications

(149 citation statements)

References 20 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…However, a small but statistically significant decrease in the proportion of cases refusing treatment by SES quintile was noted for surgery, radiation therapy, and chemotherapy. In a smaller study of CCR data from 1994 to 2000, other investigators have reported that SES (as a dichotomized variable) was not significantly associated with survival among pancreatic adenocarcinoma cases on adjusted analysis (18). However, cases with low SES were noted to be less likely to receive surgical treatment.…”

Section: Discussionmentioning

confidence: 94%

“…However, cases with low SES were noted to be less likely to receive surgical treatment. Effect modification to address the interaction of SES and treatment variables on survival of African-American cases was not done in that study, and the investigators comment in their discussion that further research is needed to explore apparent treatment disparities (18).…”

Section: Discussionmentioning

confidence: 99%

“…Geocoding to a particular street address in CCR is not available for 5.5% of cases, and in these instances, cases were randomly allocated to census block groups within their county of origin as described previously (8). The SES variable in CCR and its relationship to race/ ethnicity have been analyzed in previous epidemiologic studies of the breast, colon, prostate, ovary, nasopharynx, cutaneous melanoma, and pancreas (8,(16)(17)(18)(19)(20)(21). Quintiles for the SES score were used for analysis, with SES-1 and SES-5 denoting the lowest and highest SES quintiles, respectively.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Race, Socioeconomic Status, Treatment, and Survival Time among Pancreatic Cancer Cases in California

Zell

Rhee²,

Ziogas

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

129

120

View full text Add to dashboard Cite

Background: Poor survival in pancreatic adenocarcinoma is associated with African-American race and also with low socioeconomic status (SES). However, it is not known whether the observed poor survival of African-American pancreatic adenocarcinoma cases is due to SES itself and/or treatment disparities. We set out to determine this using the large, population-based California Cancer Registry (CCR) database as a model. Methods: We conducted a case-only analysis of CCR data (1989)(1990)(1991)(1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003), including descriptive analysis of relevant clinical variables and SES. The SES variable used has been derived from principle component analysis of census block level CCR data linked to census data to address seven major indicators of SES. Overall survival univariate analyses were conducted using the Kaplan-Meier method. Multivariate survival analyses were done using Cox proportional hazards ratios (HR).

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Race, Socioeconomic Status, Treatment, and Survival Time among Pancreatic Cancer Cases in California

Zell

Rhee²,

Ziogas

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

129

120

View full text Add to dashboard Cite

show abstract

“…Due to the lack of early diagnosis and high incidence of metastatic disease at initial diagnosis, only 15-20% of patients are resectable. [2][3][4] Even so, the 5 y survival rate among those radically operated patients is only about 5-20%. 2,5,6 To date, chemotherapy still remains the most important adjuvant therapy in patients with pancreatic malignancies.…”

Section: Introductionmentioning

confidence: 99%

RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy

Zhang

et al. 2012

Cancer Biology & Therapy

View full text Add to dashboard Cite

These authors contributed equally to this work. Keywords: nanoparticles, albumin, RGD, FITC, delivery, pancreatic cancer, therapyIntegrin avb3 receptor is expressed on several types of cancer cells, including pancreatic cancer cells, and plays an important role in tumor growth and metastasis. The ability to target the integrin avb3 receptor on cancer cells increases the efficacy of targeted therapy and reduces the side effects. The aim of this study is to develop a novel arginine-glycineaspartic acid (RGD) peptide-conjugated albumin nanoparticle to enhance the intracellular uptake of anticancer drug into the pancreatic cancer cells through receptor-mediated endocytosis. In cellular uptake studies, the fluorescent signal of RGD-conjugated BSANPs in BxPC3 cells was higher than that of BSANPs without RGD conjugation as determined by fluorescence spectrophotometer. We also found that BSANPs bound to BxPC3 cells in a time-and concentration-dependent manner. The uptake of RGD-conjugated BSANPs by pancreatic cancer cells was inhibited by an excess amount of free RGD peptide, indicating that the binding and/or uptake were mediated by the avb3 receptor. Furthermore, the nanoparticles were found to be located close to the nuclei by using laser scanning confocal microscopy. Besides, no significant in vitro cytotoxicity was observed as measured with MTT assay. Both in vitro and in vivo antitumor efficacy was improved by targeting gemcitabine-loaded nanoparticles to BxPC-3 cells using RGD peptides. Therefore, the RGD-conjugated BSANPs hold great potential as an effective drug delivery system to deliver therapeutic agents to pancreatic cancer.

show abstract

“…A recent study from New England, for example, showed that a higher SES is significantly associated with improved overall survival following pancreatic cancer resection [5], thereby indicating a relationship between SES and the quality of care delivered and outcomes. One of the largest population-based studies on pancreatic cancer survival, conducted in California, showed that poorer patients were less likely to undergo resection and less likely to survive this malignancy and that median survival increased with SES [6]. Accordingly, Zell et al reported a poorer pancreatic cancer survival for underprivileged minorities with lower SES due to treatment differences [7].…”

Section: Introductionmentioning

confidence: 99%

Postresection survival outcomes of pancreatic cancer according to demographic factors and socio-economic status

Kuhn

Koscielny

Glowka

et al. 2010

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. M A N U S C R I P T A C C E P T E D ARTICLE IN PRESS M A N U S C R I P T A C C E P T E D ARTICLE IN PRESS Kuhn et al. 2 Abstract AIM:Aim of the study was to evaluate the impact of demographic factors (DGF) and socioeconomic status (SES) on survival after pancreatic cancer resection in a German setting. METHODS:Patients with pancreatic adenocarcinoma and pancreaticoduodenectomy were identified from our pancreatic resection database (1989)(1990)(1991)(1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008). DGF, SES, survival and tumor-related information were obtained from hospital records, a registry office questionnaire, and telephone interviews with patients, relatives and general practitioners. RESULTS:Follow-up was completed in 117 patients. Median overall survival and 5-year survival rate was 22 month and 10%, respectively. Survival significantly improved over time with a 16% 5-year survival and a median survival of 27 month for recent patients. The longest survival period with a median of 63 month was observed for patients with AJCC stage I. Tumorrelated factors and treatment period, but not SES influenced survival after pancreatic cancer resection in our cohort. CONCLUSIONS:To our knowledge, this is the first study to explore survival from pancreatic cancer according to DGF and SES in a German setting. Disparities in survival among our patients depend solely on tumor-related factors and treatment period and could not be explained by SES including key factors like income or type of health insurance. The comparable postresection outcome of patients with low and high SES at our department could be in part due to the universal German multi-payer health system, based on compulsory enrolment for the majority, which seems not to support healthcare inequalities seen in other OECD countries.

show abstract

Survival Among Patients with Adenocarcinoma of the Pancreas: A Population-based Study (United States)

Cited by 177 publications

References 20 publications

Race, Socioeconomic Status, Treatment, and Survival Time among Pancreatic Cancer Cases in California

Race, Socioeconomic Status, Treatment, and Survival Time among Pancreatic Cancer Cases in California

RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy

Postresection survival outcomes of pancreatic cancer according to demographic factors and socio-economic status

Contact Info

Product

Resources

About